Find a Clinical Trial

Showing 81 - 90 of 293 Trials

ANBL19P1: A Pilot Study of Dinutuximab, Sargramostim(GM-CSF), and Isotretinoinin Combination with Irinotecan and Temozolomide in the Post-ConsolidationSetting for High-Risk Neuroblastoma

Principal Investigator:

Justine Kahn, MD

Contact Number:

212-342-5162

NCT Number:

NCT04385277

Population:

Pediatrics/Adult

Phase:

II

This is a pilot study to find out if it is possible to give chemotherapy with the very commonly used immunotherapy treatment in the treatment of newly diagnosed patients with high risk neuroblastoma (HR NBL). Immunotherapy is the last phase of treatment for HR NBL patients and is very commonly given using dinutuximab, GM-CSF, and isotretinoinin. This study is looking at where it is possible to add 2 standard chemotherapy drugs (irinotecan and temozolomide) to immunotherapy (dinutuximab, GM-CSF, and isotretinoinin) without significant side effects. This treatment would occur after the first 2...
A Randomized, Double-Blind, Placebo-Controlled Trial ofTomivosertib in Combination With Anti-PD-(L)1 Therapy inSubjects With Non-Small Cell Lung Cancer as First-Line Therapyor When Progressing on Single-Agent First-LineAnti-PD-(L)1 Therapy

Principal Investigator:

Brian Henick, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT04622007

Population:

Adult

Phase:

II

The purpose of the study is to see whether tomivosertib in combination with pembrolizumab treatment slows down the growth of cancers. The study drug, tomivosertib, works by inhibiting the activity of proteins in a pathway that allow tumor cells to grow and go unnoticed by your immune system. This study will evaluate the safety and antitumor activity of tomivosertib versus placebo in subjects with Non-Small Cell Lung Cancer. There are two study arms for this study. Treatment arm A, in addition to taking study drug you will continue to receive pembrolizumab as either 200 mg by infusion at every...
A Phase 2 Study of DS-8201a (NSC#807708, IND#153036) in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma

Contact Number:

(212) 342-5162

NCT Number:

NCT04616560

Population:

Pediatrics/Adult

Phase:

II

The purpose of this study is to find out how well DS-8201a works in treating recurrent osteosarcoma (osteosarcoma that has come back after treatment) and what side effects is has on adolescents and young adults with HER2 positive recurrent osteosarcoma. The treatment involves giving DS-8201a through a vein (IV) once every 3 weeks. This 3 week time period is known as a cycle. You can receive up to 35 cycles (or about 24 months) of treatment as long as your tumor does not grow too much and you are not having any bad side effects. Are you Eligible? (Inclusion Criteria) Patients must have a...
A Multi-Center Phase II study of Ruxolitinib in Solid Organ Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma

Principal Investigator:

Richard D Carvajal, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT04807777

Population:

Adult

Phase:

II

The purpose of this study is to test the study drug ruxolitinib to see how well the drug works on your disease. This study will also explore potential biomarkers for ruxolitinib by examining your blood and tissue for genes and proteins that can help identify and/or predict whether a therapy would benefit someone or not. Your tissue samples contain biomarkers such as proteins. Due to your illness, these proteins can be abnormal. For example, there can be too many proteins, or the proteins may be overactive. These abnormal proteins may promote cancer growth. Testing on your tumor samples allows...
A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy withClindamycin and Triamcinolone in Glioblastoma Patients Treated with Tumor Treating Fields

Principal Investigator:

Fabio M. Iwamoto, MD

Contact Number:

212-342-5162

NCT Number:

NCT04469075

Population:

Adult

Phase:

II

triamcinolone with Tumor Treating Fields (TTFields) in malignant glioma. Below you will find a summary of key information about this research study that will explain what the study is about, what you will be asked to do, how long you may be in the study, and the risks and benefits of participating in the study. The purpose of this study whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields. Are you Eligible? (Inclusion Criteria) you are 18 years of age or older Diagnosis of newly diagnosed GBM or any malignant glioma with plan to...
A phase II trial with a safety lead-in to evaluate the addition of APX005M, a CD40agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advancedsarcoma

Principal Investigator:

Matthew A. Ingham, MD

Contact Number:

212-342-5162

NCT Number:

NCT03719430

Population:

Adult

Phase:

II

The purpose of this study is to evaluate the effectiveness of a new investigational drug, APX005M, used in combination with the standard (or “usual”) treatment for these types of sarcoma. The standard treatment is doxorubicin (a chemotherapy) and olaratumab (a “targeted” drug which works against a protein that makes sarcomas grow). The investigators believe that doxorubicin and olaratumab, the standard treatment, may work better when combined with APX005M. The purpose of this clinical trial is to evaluate the safety of doxorubicin, olaratumab and APX005M when used...
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT03866382

Population:

Adult

Phase:

II

This purpose of this study is to test the effectiveness of cabozantinib with nivolumab and ipilimumab in rare genitourinary cancers that have no standard treatment options. Are you Eligible? (Inclusion Criteria) Do you have confirmed diagnosis of one of the following cancers? -small cell carcinoma of the bladder; -adenocarcinoma of the bladder; -squamous cell carcinoma of the bladder; -plasmacytoid urothelial carcinoma; -any penile cancer; -sarcomatoid renal cell carcinoma; -sarcomatoid urothelial carcinoma; -renal medullary carcinoma or other miscellaneous histologic variants of the...
A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Principal Investigator:

Amer Assal, MD

Contact Number:

212-342-5162

NCT Number:

NCT04071366

Population:

Adult

Phase:

II

Patients who will be recieving immune effector cell (IEC) therapy for the treatment of their cancer are being asked to participate in this study. IEC can produce a harmful side effect called Cytokine Release Sydnrome (CRS). CRS involves a release of a large amount of proteins into the blood stream. This may cause changes in blood pressure and heartbeat, flu-like symptoms (nausea, fever, and chills), and/or affect lung/liver/kidney function. It may also cause certain brain-related symptoms, such as dizziness, weakness, confusion, difficulty speaking, and/or decreased brain function (possible...
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475(Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE667)

Principal Investigator:

Justine Kahn, MD

Contact Number:

212-342-5162

NCT Number:

NCT03407144

Population:

Pediatrics/Adult

Phase:

II

This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults (ages 3 to 25) with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy. Immunotherapy like pembrolizumab may cause changes in the immune system that can get in the way of the tumor cells ability to grow and spread. Are you Eligible? (Inclusion Criteria) Patients must be between the ages of 3 and 25 on the day of signing informed consent Patients must have newly diagnosed, pathologically confirmed...
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATICMELANOMA

Principal Investigator:

Benjamin Izar, MD

Contact Number:

212-342-5162

NCT Number:

NCT04698187

Population:

Adult

Phase:

II

The purpose of this study is to determine the safety and efficacy of CMP-001 when given in combination with nivolumab for patients with unresectable (not capable of being surgically removed) or metastatic (cancer spreads to a different body part from where it started) melanoma. CMP-001will be given as an injection into the tumor and nivolumab will be given intravenously (into the vein). The study will collect certain lab tests in your blood and/or tumor changes while on CMP-001 plus nivolumab therapy combination so we can better understand how the drug is working. Are you Eligible? (Inclusion...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages